Ipsen Reports Strong Sales and Raises 2025 Guidance

Ipsen, a global biopharmaceutical firm, reported a sales growth of 12.1% at constant exchange rates for the first nine months of 2025. The growth, observed across all three therapeutic areas, was bolstered by products like Iqirvo®, Bylvay®, and Somatuline®. The company upgraded its financial guidance for the full year, forecasting a total sales growth of around 10% at constant exchange rates and a core operating margin of about 35% of total sales.

Additionally, Ipsen announced its proposed acquisition of ImCheck Therapeutics, aimed at bolstering its oncology pipeline. This acquisition involves ImCheck's promising Phase II asset, leading to expansion in immuno-oncology therapies. Ipsen's Chief Executive Officer, David Loew, highlighted the company's momentum and strategic initiatives aimed at advancing medical sciences to benefit patients worldwide.